In the News
DRS. Mark GLADWIN AND Jason ROSE WERE FEATURED IN THE UPMC PHYSICIAN JOURNAL FOR THEIR WORK ON THE CO ANTIDOTE
Pittsburgh, PA (March 31, 2022) – The video features interviews with Dr. Mark Gladwin and Dr. Jason Rose discussing the production and effectiveness of the modified neuroglobin molecule.
GLOBIN SOLUTIONS, INC. AWARDED NATIONAL INSTITUTES OF HEALTH FAST-TRACK SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT
PITTSBURGH, PA, (March 1, 2020) – Globin Solutions, Inc., a startup biotechnology company formed by scientists from the University of Pittsburgh, is pleased to announce that the company has been awarded a Fast-Track Small Business Technology Transfer Grant (STTR) by the National Institutes of Health (NIH) National Institute of Environmental Health Sciences. The award of up to $1.75 million dollars will support the pre-clinical development of a novel carbon monoxide (CO) poisoning scavenging agent over the next 34 months.
Stopping a Silent Killer – Pitt Innovator Maintains Bonds to Pitt as he Launches Startup to Break Bonds of Carbon Monoxide in Blood
PITTSBURGH, PA, June 29, 2018 (University of Pittsburgh, Innovation Institute) – Thanks to a cultural and policy shift at the University, [Jason] Rose has been able to license a technology that he has co-developed in the lab and serve as the CEO of a startup built on that technology while maintaining his research and clinical duties as assistant professor.
“We wanted to run our own company but we didn’t want to leave our positions at Pitt. This is something you probably couldn’t do three years ago,” he said. “We are trying to be an example of what you can do today at Pitt,” he said.
Pitt startup working to treat carbon monoxide poisoning raises $5 million
PITTSBURGH, PA, May 17, 2018 (Pittsburgh Post-Gazette)– A year-old University of Pittsburgh startup company has raised $5 million in Series A funding as it develops an antidote for carbon monoxide poisoning.
Tus Science & Technology Service Group of China led the funding round for Globin Solutions Inc. with participation from UPMC Enterprises, the commercialization arm of the Downtown-based hospital and health insurance giant.
The technology that created the antidote administered intravenously was licensed from Pitt and the funding will support pre-clinical development of the new medicine, said Jason Rose, Globin CEO and assistant professor of medicine at Pitt’s School of Medicine.
Biotech startup developing carbon monoxide poisoning antidote closes $5M Series A
PITTSBURGH, PA, May 11, 2018 (MedCity News) – A biotech startup formed by a group of scientists at the University of Pittsburgh has closed a Series A funding round. Globin Solutions raised more than $5 million for an antidote to treat carbon monoxide poisoning.
The funding will be used to support preclinical development of Globin Solutions‘ lead compound, optimizing the manufacturing and ensuring that the treatment is safe in animals.
Pittsburgh startup Globin Solutions, Inc. launches with $5 Million Series A round to develop carbon monoxide poisoning antidote
Pittsburgh, PA (April 30th, 2018) – Globin Solutions, Inc., a startup biotechnology company formed last year by scientists from the University of Pittsburgh, today announced completion of over $5 million in Series A funding for the creation of an antidote to carbon monoxide poisoning. The round was led by Tus S&T Service Group with participation from UPMC Enterprises, the commercialization arm of UPMC.
Atlas Venture, F-Prime Capital Partners and SV Health Investors to Host Symposium Featuring Therapeutics Startup Ideas From World’s Top Academic Research Institutions
CAMBRIDGE, Mass., April 12, 2018 (GLOBE NEWSWIRE) — Boston-area venture capital firms Atlas Venture, F-Prime Capital Partners and SV Health Investors have partnered to create Science 2 Startup, an invitation-only symposium aimed at strengthening connections between biotech investors and therapeutics researchers at the world’s top academic research institutions. Science 2 Startup will take place on April 24, 2018, in Cambridge at the Broad Institute of MIT and Harvard.
Pitt-Developed Molecule Could Be First Antidote for Carbon Monoxide Poisoning
PITTSBURGH, Dec. 7, 2016 – Researchers from the University of Pittsburgh School of Medicine and UPMC have engineered a protein that reverses carbon monoxide (CO) poisoning in mice, a discovery that could potentially lead to the creation of the first antidote in humans to the often deadly poisoning, according to research published today in the journal Science Translational Medicine.